Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

BACKGROUND: Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio [HR]...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Choung Soo, Choi, Young Deuk, Lee, Sang Eun, Lee, Hyun Moo, Ueda, Takeshi, Yonese, Junji, Fukagai, Takashi, Chiong, Edmund, Lau, Weber, Abhyankar, Sarang, Theeuwes, Ad, Tombal, Bertrand, Beer, Tomasz M., Kimura, Go
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502144/
https://www.ncbi.nlm.nih.gov/pubmed/28682871
http://dx.doi.org/10.1097/MD.0000000000007223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502144/
https://www.ncbi.nlm.nih.gov/pubmed/28682871
http://dx.doi.org/10.1097/MD.0000000000007223

Ejemplares similares